To study the use and side effects of Netarsudil 0.02 percent eye drops in patients of glaucoma.
Phase 3
- Conditions
- Health Condition 1: H401- Open-angle glaucoma
- Registration Number
- CTRI/2024/05/068149
- Lead Sponsor
- orthern Railway Central Hospital Basant Lane Aram Bag Paharganj New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Already diagnosed case of POAG on one of the standard drug that will be Timolol 0.5 percent eye drop for more than 1month.
2. Age at least 45 years and above.
3 .IOP more than 17mmhg and less than 25 mmhg.
4. BCVA 6/9 or better by Snellens chart.
Exclusion Criteria
Any ocular disease likely to affect IOP.
Any pathology of eye affecting media clarity.
Any infective /inflammatory pathology of eye at screening time.
Any ocular trauma in last 6 month .
CCT OF patients more than 625 micron.
Hypertension.
Advanced changes of glaucomatous optic nerve.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method